ArticleJournal of diabetes science and technology2026
How Continuous Glucose Monitoring Reports Inform Clinical Decision-Making for Older Adults With Type 2 Diabetes: Mapping Clinical Workflow to Situation Awareness.
Article in Journal of diabetes science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOlder adults with type 2 diabetes experience high risk of hypoglycemia, yet clinicians often lack actionable glucose data to guide individualized treatment decisions. This study examined how standardized continuous glucose monitoring (CGM) reports inform clinicians' decision-making using Endsley's situation awareness (SA) framework.
methodsWe conducted semi-structured interviews. Thirty clinicians reviewed three simulated older adult type 2 diabetes cases before and after reviewing CGM reports. Data saturation was achieved, consistent with qualitative research standards. Using an SA informed framework, we analyzed the proportion of clinicians referencing specific data elements and describing changes in diagnostic reasoning and treatment decisions.
resultsAfter CGM data review, clinicians frequently revised assessments and plans. Most clinicians (90%) incorporated time-in-range metrics, while 93% identified previously unrecognized hypoglycemia or nocturnal patterns. Continuous glucose monitoring data led 86% of clinicians to modify their original treatment plan, including deprescribing high-risk agents (eg, sulfonylureas), adjusting insulin timing or dosing, or initiating safer alternatives (eg, SGLT-2 inhibitors, GLP-1 receptor agonists). Clinicians also identified multiple barriers to treatment implementation, including cost, medication access, housing instability, and limited food security.
conclusionsContinuous glucose monitoring data-compared with A1C alone-provided meaningful, actionable information that improved individualized treatment decisions for older adults with type 2 diabetes. Continuous glucose monitoring data enhanced clinicians' perception, comprehension, and projection across the SA continuum, fostering more confident diagnostic reasoning and safer treatment strategies. These findings inform the design of SA-based clinical decision-support tools to better integrate CGM data, address contextual barriers, and optimize management of older adults with type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.